Tier 2 — strong

Beneficial effects of the bioflavonoids curcumin and quercetin on early function in cadaveric renal transplantation: a randomized placebo controlled trial

Daniel Shoskes, Chantale Lapierre, Marcia Cruz-Correa, Nicolas Muruve, Reinaldo Rosario, Beth Fromkin, Mauro Braun, John Copley
Transplantation 2005 80(11):1556

Bibliography

PubMed
PMID 16371925
DOI
10.1097/01.tp.0000183290.64309.21
Funding
Funding was not specified in the indexed record or the disclosure metadata available for this entry.
Competing interests
A competing-interest declaration was not available in the indexed record or the disclosure metadata used for this entry.

Study snapshot

DesignRandomized placebo-controlled renal-transplant trial
ModelHuman intervention research
Sample43 recipients enrolled; 4 withdrew
InterventionOne or two capsules containing curcumin 480 mg plus quercetin 20 mg per capsule, versus placebo
Duration1 month after transplantation
EndpointsSource-specific outcomes described in the key findings

What the study showed, in plain terms

Published in 2005, this source examined kidney and cancer research. Design: Randomized placebo-controlled renal-transplant trial. Sample/model: 43 recipients enrolled; 4 withdrew. The exposure or intervention was One or two capsules containing curcumin 480 mg plus quercetin 20 mg per capsule, versus placebo. Follow-up or treatment period: 1 month after transplantation.

Early graft-function measures favored the combination, with lower creatinine in the higher-dose group.

Small multi-ingredient perioperative trial. It cannot establish quercetin-only benefit or justify unsupervised supplementation in transplant recipients.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin Side Effects and Safety: A Practical Guide. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • Early graft-function measures favored the combination, with lower creatinine in the higher-dose group.
  • The recorded outcome domains were Source-specific outcomes described in the key findings.
  • The result applies to the tested exposure: One or two capsules containing curcumin 480 mg plus quercetin 20 mg per capsule, versus placebo; 1 month after transplantation.

What this study can and cannot tell us

  • Small multi-ingredient perioperative trial. It cannot establish quercetin-only benefit or justify unsupervised supplementation in transplant recipients.
  • An individual controlled trial must be interpreted alongside its comparator, sample size, endpoint selection and independent replication. It does not validate a different commercial formulation or a general longevity claim.
  • Source basis: Source check: PubMed abstract and indexed metadata; full methods were not independently confirmed for this entry. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 2
[Effect of antioxidants lipin and quercetin on indices of lipid peroxidation and antioxidant system in recipients of renal allotransplants]
R O Zohrab'ian et al. · Klinichna khirurhiia · 2010

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology